Kelly Jackson, APRN
Acute Care · Murfreesboro, TNNPI 1841780178
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Boston Scientific at 39.7% of the total. 2025 is the largest year on record at $16,096, 8.2 times the $1,966 reported in 2021. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 636 payments — averaging $41.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$11K
- AbbVie$10K
- Nevro Corp.$1K
- Amgen$520
- Collegium Pharmaceutical, Inc.$513
- Biohaven Pharmaceutical Holding Company Ltd.$335
- plus $3K from 36 others
What the payments were for
- Consulting fees$6,10023%
- Speaking & faculty fees$5,07519%
- Travel & lodging$2,72310%
- Food & beverage$12,60348%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WaveWriter Alpha Prime 16$7,383
- UBRELVY$1,418
- BOTOX$904
- Omnia$422
- QULIPTA$237
- GENERAL PAIN MANAGEMENT$121
- Xofluza$114
- EVENITY$103
- AIMOVIG$103
How this compares
$26,517 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 41 | $64,248 |
| RelistorMethylnaltrexone Bromide | 19 | $53,697 |
| UbrelvyUbrogepant | 22 | $44,297 |
| LinzessLinaclotide | 75 | $39,432 |
| QuliptaAtogepant | 28 | $29,757 |
| OxycontinOxycodone Hcl | 46 | $28,971 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 914 | $26,877 |
| BelbucaBuprenorphine Hcl | 33 | $24,624 |
| Xtampza ErOxycodone Myristate | 40 | $23,294 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 838 | $20,373 |
| Oxymorphone Hcl ErOxymorphone Hcl | 11 | $18,089 |
| Pregabalin | 438 | $16,120 |
| Buprenorphine | 42 | $14,050 |
| SavellaMilnacipran Hcl | 26 | $12,277 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $11,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Linzess, Qulipta, Savella | $10,337 | $125,763151 claims |
| PfizerNurtec Odt | $252 | $64,24841 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $513 | $57,80287 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $307 | $53,69719 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $33 | $27,118165 claims |
| Redhill Biopharma Inc.Movantik | $23 | $7,70312 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $13 | $5,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.
Other acute care in Murfreesboro
- Kerri RobbinsMurfreesboro$6K
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Stephen MillerKnoxville$108K
- Shannon GraceNashville$57K
- Timothy BallardKnoxville$47K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
- Elizabeth DavidsonNashville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.